Form 4: Amarin CSO Reports Equity Vesting and New RSU Grant
Statement of Changes in Beneficial Ownership
Amarin's EVP, Chief Scientific Officer, Steven B. Ketchum, reported the vesting of restricted stock units and subsequent tax-related share withholding, alongside a new RSU grant.
Summary
- Steven B. Ketchum, EVP, Chief Scientific Officer of Amarin Corp PLC\UK (AMRN), reported transactions in the company's securities.
- On January 2, 2026, 3,688 American Depositary Shares (ADS) were acquired due to the vesting of Restricted Stock Units (RSUs).
- Concurrently, 2,041 ADSs were disposed of at a price of $13.96 to cover tax liabilities incident to the RSU vesting; this was not a market sale.
- Following these transactions, Ketchum beneficially owns 38,997 ADSs directly.
- A new grant of 3,688 Restricted Stock Units (RSUs) was reported, representing a contingent right to receive 3,688 ADSs (or 7,376 Ordinary Shares before the ADS ratio change).
- These newly granted RSUs will vest 50% on January 2, 2026, and the remaining balance on July 1, 2026.
- An ADS ratio change became effective on April 11, 2025, where one ADS now represents twenty Ordinary Shares, with proportionate adjustments made to outstanding equity awards.
Sentiment
Score: 6
Explanation: The filing indicates the vesting of equity compensation and a new grant of restricted stock units for a key executive, which is generally a positive sign for executive retention and alignment with shareholder interests. The disposition of shares was solely for tax withholding, a common practice, and not a market sale.
Positives
- Vesting of 3,688 American Depositary Shares (ADS) indicates compensation realization for the EVP, Chief Scientific Officer.
- Grant of 3,688 new Restricted Stock Units (RSUs) aligns the executive's interests with long-term company performance.
Negatives
- Disposition of 2,041 American Depositary Shares (ADS) at $13.96 for tax withholding reduces the executive's direct shareholding, though it is a standard practice for equity compensation.
Future Outlook
The remaining 50% of the 7,376 Restricted Stock Units (pre-ratio change) granted on January 10, 2025, are scheduled to vest on July 1, 2026.
Industry Context
This is a routine insider transaction filing (Form 4) and does not provide information for broader industry trends or competitor analysis. It reflects standard executive compensation practices within the pharmaceutical or biotech industry, where equity awards are common.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Award Adjustment | Implementation of an ADS ratio change effective April 11, 2025, where one American Depositary Share (ADS) now represents twenty Ordinary Shares, with proportionate adjustments to outstanding equity awards. | 04/11/2025 | Standardizes the representation of equity awards following a corporate action, ensuring consistency in share equivalency. |
Related Party Transactions
- Grant of Restricted Stock Units (RSUs) to Steven B. Ketchum, EVP, Chief Scientific Officer, under the Amarin Corporation plc 2020 Stock Incentive Plan.
- Vesting of RSUs and subsequent withholding of shares for tax liability related to executive compensation.
Stakeholder Impact
- Shareholders: The vesting and grant of equity awards to a key executive can align management's interests with shareholder value creation. The tax withholding is a routine event.
- Employees: Reflects the company's ongoing equity compensation program for its executives.
Next Steps
- Remaining balance of Restricted Stock Units (RSUs) to vest on July 1, 2026.
Key Dates
| Date | Description |
|---|---|
| 01/10/2025 | Date of RSU grant (7,376 RSUs before ADS ratio change). |
| 04/11/2025 | Effective date of the ADS ratio change (1 ADS = 20 Ordinary Shares). |
| 01/02/2026 | Date of earliest transaction, 50% vesting of RSUs, and acquisition/disposition of ADSs. |
| 01/06/2026 | Signature date of the filing. |
| 07/01/2026 | Remaining balance of RSUs to vest. |
Keywords
Amarin, AMRN, Steven B. Ketchum, Form 4, SEC filing, beneficial ownership, restricted stock units, RSU, American Depositary Shares, ADS, equity compensation, insider transaction, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.